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ABSTRACT 
Background: Objective was to determine whether pharmacological interventions reduce the 
severity of fatigue in patients with cancer or hematopoietic stem cell transplant (HSCT) 
recipients as compared to control interventions.  
Methods: We conducted a systematic review and searched MEDLINE, Embase, Cochrane 
Central Register of Controlled Trials, CINAHL and PsychINFO for randomized trials of systemic 
pharmacological interventions for the management of fatigue in patients with cancer or HSCT 
recipients. Two authors independently identified studies and abstracted data. Methodological 
quality was assessed using the Cochrane Risk of Bias tool. Primary outcome was fatigue 
severity across different fatigue scales. Data were synthesized with random effects models. 
Results:  There were 117 trials (19,819 patients) included. Pharmacological agents were: 
erythropoietins (n=31); stimulants (n=19); L-carnitine (n=6); corticosteroids (n=5); anti-
depressants (n=5), appetite-stimulants (n=3) and other agents (n=48). Erythropoietin 
(standardized mean difference (SMD) -0.52, 95% confidence interval (CI) -0.89 to -0.14) and 
methylphenidate (SMD -0.36, 95% CI -0.56 to -0.15) significantly reduced fatigue while 
modafinil/armodafinil and corticosteroids were not effective. 
Conclusions:  Erythropoietin and methylphenidate significantly reduced fatigue severity in 
patients with cancer and in HSCT recipients. Concerns regarding the safety of these agents 
may limit their usefulness.  Future research should identify effective interventions for fatigue with 
minimal adverse effects.  
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Introduction  
Cancer-related fatigue (CRF) has been increasingly recognized as one of the most 
important symptoms in patients with cancer.(1, 2) CRF has been described as an unexpected 
tiredness that is more intense and severe than fatigue experienced in healthy people.(3) CRF 
can affect up to 80-90% of cancer patients, and can occur prior to diagnosis, during cancer 
treatment and following the completion of cancer therapies.(1, 4-9) The etiology of CRF is 
multifactorial and may result from cancer itself, treatments, and comorbid medical and 
psychological conditions.(10, 11) Recipients of hematopoietic stem cell transplantation (HSCT) 
also experience fatigue, likely related to similar underlying mechanisms.(12, 13)  
A number of interventions have been investigated for the management of fatigue in 
cancer patients, including physical activity, psychological interventions, and pharmacological 
approaches, with several systematic reviews published.(14-22)  In particular, evaluation of 
pharmacological interventions is important since medications may be associated with adverse 
effects and high costs, thus necessitating a good understanding of benefits and risks to guide 
decision making. However, the pharmacological systematic reviews published to date had 
restrictive inclusion and exclusion criteria and included a limited number of studies.(18, 22) Thus, 
these studies lacked precision in estimating treatment effects and had limited power to identify 
effective interventions.  
Our primary objective was to determine whether pharmacological interventions reduce 
the severity of fatigue in patients with cancer or HSCT recipients as compared to control 
interventions.  
 
Material and Methods  
We followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses 
(PRISMA) statement for this systematic review.(23) A search for eligible trials was performed for 
randomized trials indexed from 1980 to May 11, 2017 in the following electronic databases: 
6 
 
MEDLINE, MEDLINE in-process, EMBASE, Cochrane Central Register of Controlled Trials, 
CINAHL and PsychINFO. The search strategy included Medical Subject Heading terms and text 
words that identified patients with cancer or HSCT recipients who received an intervention to 
reduce fatigue. The full search strategy is shown as Appendix 1. 
 
Study Selection and Data Abstraction  
 We defined inclusion and exclusion criteria a priori. Studies were included if participants 
were adults or children with cancer or HSCT recipients, and if the study was a fully published 
primary randomized or quasi-randomized trial with a parallel group design which evaluated a 
pharmacological intervention for the management of fatigue.  
 We excluded studies if less than 75% of participants had cancer or were undergoing 
HSCT; if fatigue was either not an end-point or reported as an adverse effect; if the intervention 
was direct cancer treatment; and if less than five participants were randomized to any study arm.  
We did not restrict inclusion by language. For the purpose of this analysis, we then limited 
studies to those using a systemically administered pharmacological agent. We did not include 
non-systemically administered pharmacological agents or studies in which only education or 
advice were provided. 
 Two reviewers (SO, PDR or LS) independently evaluated the titles and abstracts of 
publications identified by the search. Any publication considered potentially relevant by at least 
one reviewer was retrieved in full and assessed for eligibility. Inclusion of studies in this meta-
analysis was determined by agreement of two reviewers (SO, PDR or LS). Discrepancies 
between the two reviewers were resolved by consensus and adjudication by a third reviewer if 
required (LLD or LS). The Kappa statistic was used to evaluate agreement in study inclusion 
between the two reviewers. Strength of agreement was defined as slight (0.00 to 0.20), fair 
(0.21 to 0.40), moderate (0.41 to 0.60), substantial (0.61 to 0.80), or almost perfect (0.81 to 
1.00).(24) 
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Data were abstracted in duplicate by two reviewers (DT and PDR) and any 
discrepancies were resolved by consensus. We contacted authors of manuscripts when 
publications were missing primary fatigue outcome data.  
 
Outcomes  
The primary outcome was the severity of self-reported fatigue across different fatigue 
scales. We evaluated both change scores and end of intervention scores. For studies that used 
more than one fatigue scale, we a priori defined a hierarchy in which we would include scales in 
the analysis based upon prevalence. Appendix 2 shows the prevalence of reported scales in 
this systematic review. The secondary outcome was the severity of self-reported fatigue using 
the most common fatigue scale (determine after all scales categorized).  
 
Intervention and Control Groups 
The intervention was any systemically administered pharmaceutical agent. In studies 
with more than two arms, the least “active” (for example, placebo, usual care or lowest dose) 
was used as the control group. Where multiple pharmacological agents were evaluated, the 
intervention group was the highest dose or the most commonly evaluated intervention 
(determined after all interventions abstracted and categorized).   
We categorized control group type as placebo, usual care, or other pharmacological 
interventions.   
 
Study Covariates 
Study-level variables included age of participants (adult or child), cancer diagnosis 
(breast, lung, other single cancer type or more than one cancer type), inclusion of HSCT 
patients, timing of intervention (during cancer treatment, following completion of treatment or 
both during and following treatment), exclusive enrollment of palliative care patients (as defined 
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by each study), presence of fatigue as an eligibility criterion for enrollment (as defined by each 
study) and duration of intervention (< 8 weeks, ≥ 8 weeks or variable based on median duration 
reported by each study). We also evaluated methodological aspects of studies. 
 
Risk of Bias Assessment  
We used the Cochrane Collaboration’s tool for assessing the risk of bias in randomized 
trials.(25) We evaluated sequence generation, allocation concealment, blinding of participants 
and personnel, blinding of outcome assessors and attrition bias. We prioritized adequate 
sequence generation and adequate allocation concealment a priori for stratified analyses 
because of their potential effect on bias.(26) 
 
Data Analysis  
We combined data at the study level for this meta-analysis and not at the individual 
patient level.  All synthesized outcomes were continuous. For fatigue scores with missing 
summary measures, we made the following assumptions to facilitate data synthesis: the mean 
can be approximated by the median; the range contains six standard deviations, the 95% 
confidence interval (CI) contains four standard errors, and the interquartile range contains 1.35 
standard deviations. Instruments were rescaled where required such that higher scores 
reflected more fatigue. We synthesized outcomes when at least three studies within a stratum 
had available data. 
For the primary outcome of the severity of fatigue across all fatigue scales, data were 
synthesized using the standardized mean difference (SMD). For the secondary outcome of the 
most commonly used fatigue scale, data were synthesized using the weighted mean difference 
(WMD). A SMD or WMD less than 0 indicated that the mean fatigue scores were lower (better) 
in the intervention group as compared to the control group. Effect sizes were weighted by the 
inverse variance method. As we anticipated heterogeneity between studies, a random effects 
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model was used for all analyses. Statistical heterogeneity between trials was assessed using 
the I2 value, which describes the percentage of total variation across studies due to 
heterogeneity rather than chance. 
For the primary analysis, we compared individual pharmacological intervention groups to 
all control groups using all fatigue severity scales. Both change scores and end of intervention 
scores were evaluated. We also evaluated interventions against placebo where possible. A 
secondary analysis evaluating the most commonly used scale was similarly conducted.   
Potential publication bias was explored by visual inspection of funnel plots when at least 
10 studies were available for synthesis.(25) In the event of potential publication bias, the ‘‘trim 
and fill’’ technique was used to determine the impact of such bias.(27) With this technique, 
outlying studies are deleted, and hypothetical negative studies with equal weight are created.  
  Meta-analyses were conducted using Review Manager 5.2 (Cochrane Collaboration, 
Nordic Cochrane Centre). All tests of significance were two-sided, and statistical significance 
was defined as P<0.05. 
 
Results  
The flow diagram of study identification and selection is presented as Figure 1. The 
search strategy identified 11,793 citations, of which 617 were retrieved for full-text evaluation. 
Of these citations, 117 studies met the eligibility criteria and were included in this systematic 
review. Reasons for exclusion are described in Figure 1. Agreement of study inclusion between 
the two reviewers was almost perfect (kappa = 0.97, 95% CI 0.95 to 0.99). 
Table 1 and Appendix 3 describe the characteristics of the 117 included studies. These 
studies were conducted in over 30 countries. The majority (69.2%) were published on or after 
2007. All studies were conducted exclusively in adults; no pediatric patients were included in 
any of the studies. Breast cancer (15.4%) was the most common cancer diagnosis studied. 
Twenty studies (17.1%) were conducted exclusively in the palliative care setting.  
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Pharmacological interventions were as follows: erythropoietins (n=31, 26.5%), stimulants 
(n=19, 16.2%), L-carnitine (n=6, 5.1%), corticosteroids (n=5, 4.3%), anti-depressants (n=5, 
4.3%), appetite stimulants (n=3, 2.6%), and others (n=48, 41.0%) (Table 1 and Appendix 3). 
The comparison groups were placebo (n=75, 64.1%), usual care (n=26, 22.2%) and other 
pharmacological interventions (n=16, 13.7%). Fatigue assessment scales used across all the 
studies are listed in Appendix 2. The most commonly used fatigue scale was the Functional 
Assessment of Cancer Therapy (FACT) 13-item fatigue scale. Of all studies included in this 
systematic review, only 35/117 (29.9%) could be included in any synthesis because of the 
requirement to present an estimate of central tendency (mean or median) and a measure of 
variability, and to have at least three studies with such data within a stratum. The 
pharmacological agents with synthesizable data were erythropoietins, stimulants and 
corticosteroids.  
Table 2 shows the effect of evaluable pharmacological agents by either change scores 
or end of intervention scores.  In evaluating erythropoietin, only change scores could be 
evaluated as not enough studies reported end of intervention scores for any analysis. 
Erythropoietin significantly improved fatigue when compared to all controls and placebo. When 
compared to all controls, the SMD was -0.52 (95% CI -0.89 to -0.14). When restricted to studies 
that reported fatigue using FACT, erythropoietin significantly improved fatigue compared to all 
controls; WMD was -2.98 (95% CI -4.41 to -1.55).  
Table 2 also shows the effect of stimulants when compared to all control groups and 
when compared to placebo. As a group, stimulants were not effective at improving change in 
fatigue or end of intervention fatigue scores. However, when stratified by specific agent, 
methylphenidate significantly improved fatigue (SMD -0.36, 95% CI -0.56 to -0.15 and WMD -
2.87, 95% CI -4.68 to -1.07) while modafinil/armodafinil were not effective in any comparison. 
Corticosteroids did not improve fatigue (Table 2). 
Due to the small number of studies with data available for synthesis, stratified analyses 
11 
 
were unable to be conducted for L-carnitine, anti-depressants and appetite stimulants. All other 
agents were included in only one or two studies and thus, data synthesis was not possible (see 
Appendix 3). Appendix 4 illustrates the funnel plot for erythropoietin vs. all controls; no evidence 
of publication bias was observed. 
 
Discussion  
In this systematic review and meta-analysis, we found that erythropoietin and 
methylphenidate significantly improved fatigue in patients with cancer and HSCT recipients 
while modafini/armodafinill and corticosteroids were not effective. We also found that in spite of 
the conduct of a very large number of randomized trials, data synthesis was limited. Most 
interventions were studied only once or twice and even for agents which were studied more 
often, data from many studies could not be synthesized because of limited data reporting.  
While we found that erythropoietin was effective in reducing fatigue, the size of the effect 
was a WMD of 2.49 when compared to placebo according to the FACT 13-item fatigue sub-
scale. The minimally clinically important difference of the FACT 13-item fatigue sub-scale has 
been reported to be 3 to 3.5,(28) which suggests that while statistically significant, this effect is 
not meaningful to patients. Particularly when combined with the concerns regarding tumor 
protection, veno-thrombotic events and worse survival potentially associated with 
erythropoietin,(29, 30) this agent should not be used routinely in clinical practice for fatigue 
reduction.  
The other pharmacological agent which was found to be effective for fatigue was 
methylphenidate. However, the WMD of methylphenidate also did not meet the threshold for 
clinical importance. Further, a Cochrane review of methylphenidate for attention deficit 
hyperactivity disorder suggested that methylphenidate was associated with an increased risk of 
non-serious adverse events, with sleep problems and decreased appetite being most 
common.(31) Together, these issues suggest that methylphenidate should not be used routinely 
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to manage fatigue in patients with cancer and HSCT recipients but could be selectively used for 
specific patients in whom the potential benefits outweigh the disadvantages.  
None of the studies included children. This omission is important as patients with 
childhood cancer experience severe fatigue,(32, 33) and are vulnerable to long-term side effects of 
treatments.(34) It is possible that pharmacological interventions have not be applied to children 
as dosing considerations and safety concerns add complexity. However, future studies should 
consider the pediatric population when formulating eligibility criteria. 
An interesting observation was that despite the large number of randomized trials, there 
were relatively few studies with data available for meta-analysis. Although the FACT 13-item 
fatigue sub-scale was used in many of the trials, there was inconsistency in whether change 
scores or end of intervention scores were reported.  Additionally, many of the study did not 
report a measure of central tendency and a measure of variability for one of our two fatigue 
outcomes (change or end of intervention scores). The lack of well-reported fatigue data may 
raise concerns about a form of publication bias in which negative endpoints are not reported or 
data are not shown. Future randomized studies focused on fatigue reduction should be 
encouraged to explicitly report data that could be combinable in systematic reviews.   
This systematic review complements two previously published meta-analyses which 
evaluated pharmacological agent effects on fatigue in cancer patients.(18, 35) Our review adds 
important insights as the Mustian review reported many types of interventions, citing 14 studies 
of pharmacological interventions that were analyzed as a single group.(18) To inform practice, 
pharmacological agents must be evaluated separately. The Minton review, which analyzed 
specific pharmacologic interventions, is now outdated with a literature search conducted in 
2009.(35) 
The strengths of this review are its broad eligibility criteria, inclusion of publications in all 
languages and its focus on systemically administered pharmacological agents. However, our 
meta-analysis was limited by the data reported by the primary studies. Further, there was wide 
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variation in dosing and schedule among the individual pharmacological agents studied and 
because of the limited number of studies available for synthesis, stratified analyses were not 
possible. 
In conclusion, erythropoietin and methylphenidate significantly reduced fatigue severity 
in patients with cancer and in HSCT recipients although the magnitude of the benefit is of 
questionable clinical significance. Use of these agents may be further limited by concerns 
regarding their safety.  Pharmacological interventions should not be used routinely to reduce 
fatigue severity. Future meta-analysis should obtain individual data from trials to better 
understand pharmacological effects on fatigue. Research is required to identify effective 
interventions for fatigue with minimal adverse effects.  
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Table 1: Characteristics of Included Studies in the Systematic Review (N=117)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristic  No. of Studies (%) 
Study Population   
     Adults   117 (100%) 
     Children 0 (0) 
Cancer Diagnosis   
     Breast 18 (15.4%) 
     Lung 11 (9.4%) 
     Other single cancer type 25 (21.4%) 
     More than one cancer type 63 (53.8%) 
Included Hematopoietic Stem Cell Transplant Recipients 2 (1.7%) 
Timing of Intervention  
     During cancer treatment   80 (68.4%) 
     Following completion of treatment 15 (12.8%) 
     Both during and following treatment 18 (15.4%) 
     Not reported 4 (3.4%) 
Palliative Care Setting Only  20 (17.1%) 
Required Fatigue for Eligibility 28 (23.9%) 
Pharmaceutical Company Sponsor 42 (35.9%) 
Duration of Intervention  
    < 8 weeks 43 (36.8%) 
    ≥ 8 weeks 57 (48.7%) 
    Variable 17 (14.5%) 
Intervention Type  
     Erythropoietins 31 (26.5%) 
     Stimulants  19 (16.2%) 
     L-carnitine 6 (5.1%) 
     Corticosteroids 5 (4.3%) 
     Anti-depressants 5 (4.3%) 
     Appetite stimulants 3 (2.6%) 
     Other agents 48 (41.0%) 
Route of Administration  
     Oral 67 (57.3%) 
     Subcutaneous 36 (30.8%) 
     Intravenous 13 (11.1%) 
     Intramuscular 1 (0.9%) 
Control Group Type  
     Placebo 75 (64.1%) 
     Usual care 26 (22.2%) 
     Other pharmacological 16 (13.7%) 
Low Risk of Bias  
    Adequate sequence generation 68 (58.1%) 
    Adequate allocation concealment 41 (35.0%) 
    Participants and personnel blinded   44 (37.6%) 
    Outcome assessors blinded 55 (47.0%) 
    Lack of attrition bias 95 (81.2%) 
    Free of selective reporting 106 (90.6%) 
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Table 2: Effect of Erythropoietins, Stimulants and Corticosteroids on Fatigue Using All Fatigue Scales and FACT Scale* 
 Outcome is Fatigue Change Scores Outcome is End of Intervention Fatigue Scores 
Outcome 
No. of 
Studies 
No. of 
Patients 
Effect 95% CI I2 (%) P Value 
No. of 
Studies 
No. of 
Patients 
Effect 95% CI I2 (%) P Value 
ERYTHROPOIETINS 
All Scales  
All Interventions vs. 
All Controls  
14 3,037 -0.52 SMD -0.89, -0.14 96 0.007 2 NSP 
All Interventions vs. 
Placebo  
6 1,057 -0.19 SMD -0.32, -0.07 0 0.003 1 NSP 
By FACT Scale 
All Interventions vs. 
All Controls  
12 2,587 -2.98 WMD -4.41, -1.55 79 <0.001 0 NSP 
All Interventions vs. 
Placebo  
4 683 -2.49 WMD -4.06, -0.92 0 0.002 0 NSP 
STIMULANTS 
All Scales  
All Interventions vs. 
All Controls  
9 1,240 -0.16 SMD -0.34, 0.02 42 0.08 13 1,287 -0.09 SMD -0.28, 0.11 50 0.51 
All interventions vs. 
Placebo**  
9 1,240 -0.16 SMD -0.34, 0.02 42 0.08 12 1,263 -0.08 SMD -0.28, 0.12 53 0.44 
Stratified by Agent for All Scales 
Methylphenidate vs. 
All Controls  
5 369 -0.36 SMD -0.56, -0.15 0 <0.001 6 305 -0.32 SMD -0.80, 0.17 73 0.20 
Modafinil/armodafinil 
vs. All Controls  
4 871 0.01 SMD -0.21, 0.22 36 0.94 5 905 -0.04 SMD -0.17, 0.09 0 0.51 
By FACT Scale 
All Interventions vs. 
All Controls  
7 596 -1.35 WMD -3.47, 0.78 50 0.21 7 424 0.80 WMD -1.57, 3.18 0 0.51 
All Interventions vs. 
Placebo**  
7 596 -1.35 WMD -3.47, 0.78 50 0.21 7 424 0.80 WMD -1.57, 3.18 0 0.51 
Methylphenidate vs. 
All Controls  
4 346 -2.87 WMD -4.68, -1.07 0 0.002 3 150 0.71 WMD -3.18, 4.59 0 0.72 
Modafinil/armodafinil 
vs. All Controls  
3 250 1.24 WMD -2.19, 4.68 49 0.48 4 274 0.89 WMD -2.17, 3.94 3 0.57 
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Abbreviations:  FACT - Functional Assessment of Cancer Therapy; SMD - standardized mean difference; WMD - weighted mean difference; CI – 
confidence interval; NSP – no synthesis possible because too few studies 
 
* Outcomes using FACT were rescaled (multiplying by -1) so that higher scores reflected more fatigue. One study (Littlewood) contributed twice as 
results were reported separately for lymphoma and multiple myeloma groups 
 
** All synthesized studies were placebo controlled
CORTICOSTEROIDS 
All interventions vs. 
All Controls 
3 165 -0.43 SMD -1.00, 0.14 67 0.14 2 NSP 
All Interventions vs. 
Placebo ** 
3 165 -0.43 SMD -1.00, 0.14 67 0.14 2 NSP 
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Figure 1: Flow diagram Depicting Study Identification, Selection and Reasons for Exclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11,793 citations screened by 
title/abstract  
2,263 duplicates removed  
11,176 citations excluded as did not 
meet eligibility criteria  
617 full-text papers retrieved for 
detailed evaluation  
173 excluded  
   21 not fully published (abstract or thesis) 
   34 not parallel group RCT 
     3 less than 75% of patients had cancer  
     2 less than 5 patients randomized to any arm 
    10 fatigue not a study endpoint or as AE 
     1 intervention direct cancer therapy 
   91 duplicate or companion publication  
     2 unable to translate 
     9 not retrievable 
      
 
444 studies identified as 
potentially eligible  
14,056 potentially relevant 
references identified  
117 included studies 
342 excluded as not a 
pharmacological intervention  
15 studies included 
from review of SRs 
